Akili Completes Business Combination With Social Capital Suvretta Holdings Corp. I (DNAA)

Virtual Therapeutics Acquires Akili Interactive

July 2, 2024

Medical Devices

Virtual Therapeutics completed a tender offer to acquire all outstanding shares of Akili, Inc. for $0.4340 per share, with approximately 88.2% of Akili's shares tendered. Following acceptance of the tendered shares, Virtual Therapeutics' wholly owned subsidiary Alpha Merger Sub will merge into Akili, making Akili a wholly owned subsidiary and prompting Nasdaq delisting and deregistration.

Kindeva Drug Delivery (Altaris) Acquires Summit Biosciences

January 18, 2024

Medical Devices

Kindeva Drug Delivery, an operating company of healthcare investor Altaris, has acquired Summit Biosciences from its founding family shareholders. The acquisition adds Summit’s FDA- and EMA-approved 55,000 sq. ft. cGMP intranasal CDMO facility in Lexington, Kentucky, expanding Kindeva’s nasal drug‑delivery platform and global manufacturing footprint.

Altaris Capital Partners Acquires Kindeva Drug Delivery from 3M

May 1, 2020

Medical Devices

Altaris Capital Partners has acquired Kindeva Drug Delivery L.P. (formerly 3M Drug Delivery Systems) from 3M Company for $650 million in a corporate carve-out transaction. Monroe Capital provided financing and an equity co-investment to support the deal, and 3M will retain a minority interest alongside Altaris as Kindeva operates independently to pursue growth and capital investments.

Federal Street Acquisition Corp. and Thomas H. Lee Partners Complete Business Combination with Agiliti Health

January 4, 2019

Healthcare Services

Federal Street Acquisition Corp. (sponsored by an affiliate of Thomas H. Lee Partners) completed a business combination with Agiliti Holdco, the holding company of Agiliti Health, creating Agiliti, Inc. The combined company has an implied enterprise value of approximately $1.74 billion, with entities affiliated with Thomas H. Lee Partners and management holding majority ownership; Irving Place Capital was the prior owner of Agiliti Health.

SSI Strategy Acquires NDA Group AB

August 15, 2023

Healthcare Services

SSI Strategy has entered into a definitive agreement to acquire NDA Group AB, a regulatory affairs and drug development consultancy, to create an integrated life sciences consultancy offering end-to-end drug development and regulatory services. The combination, supported by SSI's private equity partner Amulet Capital Partners, expands SSI's regulatory capabilities and geographic footprint across the U.S. and Europe.

AbbVie Acquires Aliada Therapeutics for $1.4 Billion

December 11, 2024

Biotechnology

AbbVie has completed the $1.4 billion acquisition of Aliada Therapeutics, a RA Capital- and JJDC-backed biotech developing ALIA-1758, an anti‑pyroglutamate amyloid beta antibody that uses a blood‑brain‑barrier crossing technology for Alzheimer's disease. The deal brings Aliada's CNS drug‑delivery platform and lead Phase 1 asset into AbbVie's neuroscience pipeline and represents an exit for RA Capital's Raven incubator and other early investors.